From: Health of Spanish centenarians: a cross-sectional study based on electronic health records
ATCa code | Chronic medication | Men (%) | Women (%) | P value |
---|---|---|---|---|
A02B | Drugs for peptic ulcer and GERDb | 53.9 | 50.2 | n.s.c |
B01A | Antithrombotic agents | 43.6 | 39.9 | n.s. |
N02B | Other analgesics and antipyretics | 34.1 | 36.4 | n.s. |
C03C | High-ceiling diuretics | 31.5 | 34.9 | n.s. |
N05B | Anxiolytics | 13.9 | 23.4 | <0.001 |
N06A | Antidepressants | 12.8 | 14.7 | n.s. |
N05C | Hypnotics and sedatives | 9.9 | 14.7 | <0.05 |
N05A | Antipsychotics | 11.4 | 14.2 | n.s. |
C09A | ACEd inhibitors, plain | 7.3 | 14.9 | <0.001 |
B03A | Iron preparations | 12.8 | 10.7 | n.s. |
C08C | Selective calcium channel blockers with mainly vascular effects | 13.9 | 10.3 | n.s. |
C05C | Capillary stabilizing agents | 4.4 | 11.4 | <0.05 |
C01D | Vasodilators used in cardiac diseases | 8.1 | 10.3 | n.s. |
C09C | Angiotensin II receptor blockers, plain | 7.0 | 9.0 | n.s. |
M02A | Topical products for joint and muscular pain | 6.1 | 9.0 | n.s. |
C09D | Angiotensin II receptor blockers, combinations | 5.9 | 8.4 | n.s. |
S01E | Antiglaucoma preparations and miotics | 7.7 | 7.3 | n.s. |
A06A | drugs for constipation | 8.1 | 6.7 | n.s. |
M01A | Antiinflammatory and antirheumatic products, non-steroids | 10.3 | 6.1 | <0.05 |
C01A | Cardiac glycosides | 8.1 | 6.6 | n.s. |
N06B | Psychostimulants, agents used for ADHDe and nootropics | 8.8 | 6.0 | n.s. |
R05C | Expectorants, excl. Combinations with cough suppressants | 8.4 | 5.5 | n.s. |
A10B | Blood glucose lowering drugs, excl. Insulins | 5.1 | 5.9 | n.s. |
V06X | General nutrients | 5.5 | 5.6 | n.s. |
B03B | Vitamin B12 and folic acid | 5.1 | 5.5 | n.s. |
C07A | Beta blocking agents | 4.4 | 5.7 | n.s. |
N02A | Opioids | 2.2 | 6.2 | <0.05 |
G04C | Drugs used in benign prostatic hypertrophy | 26.0 | 0.0 | <0.001 |
C10A | Lipid modifying agents, plain | 6.6 | 4.3 | n.s. |
C04A | Peripheral vasodilators | 5.5 | 4.1 | n.s. |
R03A | Adrenergics, inhalants | 7.3 | 3.7 | <0.05 |
R03B | Other drugs for obstructive airway diseases, inhalants | 7.3 | 3.7 | <0.05 |
S01X | Other ophthalmologicals | 3.7 | 4.4 | n.s. |
C09B | ACE inhibitors, combinations | 3.7 | 4.3 | n.s. |
D01A | Antifungals for topical use | 4.0 | 4.2 | n.s. |
C03D | Potassium-sparing agents | 5.9 | 3.6 | n.s. |
C03E | Diuretics and potassium-sparing agents in combination | 1.1 | 4.6 | <0.05 |
A03F | Propulsives | 1.1 | 4.1 | <0.05 |
R06A | Antihistamines for systemic use | 5.5 | 3.1 | n.s. |
C01E | Other cardiac preparations | 3.7 | 3.4 | n.s. |
C03B | Low-ceiling diuretics, excl. Thiazides | 2.6 | 3.6 | n.s. |
C08D | Selective calcium channel blockers with direct cardiac effects | 3.7 | 2.7 | n.s. |
A12A | Calcium | 0.7 | 3.3 | <0.05 |
A12B | Potassium | 1.8 | 3.1 | n.s. |
D07A | Corticosteroids, plain | 4.8 | 2.3 | <0.05 |
M04A | Antigout preparations | 5.9 | 2.0 | <0.001 |
N03A | Antiepileptics | 1.8 | 3.0 | n.s. |
N07C | Antivertigo preparations | 2.9 | 2.6 | n.s. |
J01 M | Quinolone antibacterials | 4.0 | 1.9 | n.s. |
H02A | Corticosteroids for systemic use, plain | 3.7 | 1.7 | n.s. |
H03A | Thyroid preparations | 1.1 | 2.3 | n.s. |
J01X | Other antibacterials | 2.9 | 1.4 | n.s. |
J01C | Beta-lactam antibacterials, penicillins | 2.6 | 1.4 | n.s. |
N06D | Anti-dementia drugs | 1.8 | 1.6 | n.s. |
V06Z | General nutrients | 2.9 | 1.4 | n.s. |
S01A | Antiinfectives | 0.7 | 1.7 | n.s. |
A10A | Insulins and analogues | 1.5 | 1.4 | n.s. |
C03A | Low-ceiling diuretics, thiazides | 0.7 | 1.4 | n.s. |
J01D | Other beta-lactam antibacterials | 1.1 | 1.4 | n.s. |
R05D | Cough suppressants, excl. Combinations with expectorants | 2.3 | 1.0 | n.s. |
H03B | Antithyroid preparations | 0.7 | 1.1 | n.s. |